Aligos Therapeutics Announces First Participant Dosed in the Phase 1 Study of its Potentially Best-in-Class Antisense Oligonucleotide ALG-170675 by its Partner Amoytop in China
Globe Newswire•12/08/2026•16:05 ET
0
Whiz Insights
Get started
Create a free account to read the full story.